Bayer AG today announced the global expansion of its life science incubator network, Bayer Co.Lab, to Shanghai, China, and Kobe, Japan.

拜耳公司今天宣布将其生命科学孵化器网络拜耳公司实验室全球扩展到中国上海和日本神户。

This move establishes new sites for the Bayer Co.Lab program at the hotspots of innovation in China as well as in Japan. Recognizing that innovation can emerge from any part of the world, this expansion strategically broadens Bayer's external innovation network, elevating the importance of early-stage incubation.

这一举措为拜耳公司实验室计划在中国和日本的创新热点建立了新的地点。认识到创新可以从世界任何地方出现，这种扩张战略性地拓宽了拜耳的外部创新网络，提高了早期孵化的重要性。

It enhances Bayer's access to innovations while offering biotech start-ups access to both physical facilities and comprehensive support, ensuring an environment conducive to growth. .

它增强了拜耳获得创新的机会，同时为生物技术初创企业提供物理设施和全面支持，确保有利于增长的环境。。.

'Expanding the Bayer Co.Lab incubator network is a key element of our company’s innovation strategy - finding solutions for pressing healthcare challenges and unmet medical needs through collaborative approaches,' said Juergen Eckhardt, M.D., Head of Pharmaceuticals Business Development, Licensing & Open Innovation at Bayer AG.

拜耳公司药品业务发展，许可和开放创新负责人Juergen Eckhardt博士说：“扩大拜耳公司实验室孵化器网络是我们公司创新战略的一个关键要素-通过合作方式为紧迫的医疗保健挑战和未满足的医疗需求寻找解决方案。”。

'Through the Bayer Co.Lab program we can identify early-stage innovations and serve as a catalyst driving the best ideas toward realization.' .

“通过拜耳公司的实验室计划，我们可以确定早期的创新，并作为推动实现最佳想法的催化剂。”。.

At the new site in China, Bayer will collaborate with Shanghai Pharmaceuticals to focus on oncology and cell and gene therapy (CGT) innovations. In Japan, Bayer and its collaborators will focus on multiple therapy areas and CGT-based innovations.

在中国的新网站，拜耳将与上海制药公司合作，专注于肿瘤学，细胞和基因治疗（CGT）创新。在日本，拜耳及其合作者将专注于多个治疗领域和基于CGT的创新。

At the Bayer Co.Lab site in Cambridge, MA, USA, entrepreneurs like Portal Bio, AI Proteins, Typewriter Therapeutics, Flux Therapeutics and AIRNA are already working on pioneering unique advancements in CGT delivery technologies and innovative therapeutic solutions.

在美国马萨诸塞州剑桥的拜耳公司实验室，Portal Bio，AI Proteins，Typewriter Therapeutics，Flux Therapeutics和AIRNA等企业家已经在CGT交付技术和创新治疗解决方案方面开创了独特的进步。

'Bayer Co.Lab provides more than just lab and office space - it opens doors to mentoring, training and a nexus of industry expertise, partners, and collaboration opportunities, accessible regardless of a resident’s location,' said Andrew Wong, Global Head of Bayer Co.Lab at Bayer U.S. LLC. 'These resources are crucial in the journey from concept through development, and we are thrilled to welcome our first residents as they embark on that journey with us.' .

拜耳美国有限责任公司全球负责人安德鲁·黄（Andrew Wong）说：“拜耳公司实验室不仅提供实验室和办公空间-它为指导，培训以及行业专业知识，合作伙伴和合作机会之间的联系打开了大门，无论居民的位置如何，这些资源在从概念到发展的过程中至关重要，我们很高兴欢迎我们的第一批居民与我们一起旅行。.

In 2024 Bayer will open a Co.Lab site at the company's global Pharmaceuticals divisional headquarters in Berlin, Germany, which will serve as a hub for breakthrough discoveries, with a particular focus on cell and gene therapies and modality platforms.

2024年，拜耳将在德国柏林的公司全球制药部门总部开设一个Co.实验室，该实验室将作为突破性发现的中心，特别关注细胞和基因治疗以及模式平台。

About Bayer Co.Lab

关于拜耳公司实验室

Bayer Co.Lab is a global network of life science incubators established to catalyze innovation and collaboration within vibrant biotech ecosystems and designed to support pioneering entrepreneurs across multiple therapeutic areas. Beyond providing state-of-the-art laboratories and collaborative workspaces, Bayer Co.Lab offers global mentorship programs and direct access to Bayer's wide-ranging expertise and vast network of industry-leading partners.

拜耳公司实验室是一个全球生命科学孵化器网络，旨在促进充满活力的生物技术生态系统内的创新和合作，旨在支持多个治疗领域的开拓性企业家。除了提供最先进的实验室和协作工作空间外，拜耳公司实验室还提供全球指导计划，并直接访问拜耳广泛的专业知识和庞大的行业领先合作伙伴网络。

In alignment with Bayer's commitment to accelerating solutions that address significant medical needs, Bayer Co.Lab embodies the company's forward-thinking approach to a collaborative future in healthcare innovation. All Bayer Co.Lab locations are accepting applications from early-stage life science start-ups..

为了与拜耳致力于加速解决重大医疗需求的解决方案保持一致，拜耳公司实验室将公司的前瞻性思维方式体现在医疗保健创新的合作未来。所有拜耳公司的实验室都接受早期生命科学初创企业的申请。。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses.

拜耳是一家在医疗保健和营养生命科学领域拥有核心竞争力的全球企业。其产品和服务旨在通过支持努力掌握日益增长和老龄化的全球人口所带来的主要挑战，帮助人们和地球茁壮成长。拜耳致力于推动可持续发展并对其业务产生积极影响。

At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros..

与此同时，该集团旨在通过创新和增长提高其盈利能力和创造价值。拜耳品牌代表着全球的信任，可靠性和质量。在2022财年，该集团雇用约101000人，销售额为507亿欧元。。